🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden flag Sweden · Delayed Price · Currency is SEK
11.12
0.00 (0.00%)
Nov 20, 2026, 5:29 PM CET

Egetis Therapeutics AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
70.162.446.157.622.638.2
Other Revenue
-0.1-----
7062.446.157.622.638.2
Revenue Growth
26.13%35.36%-19.96%154.87%-40.84%-6.05%
Cost of Revenue
60.85011.611142.696.6
Gross Profit
9.212.434.546.6-120-58.4
Selling, General & Admin
312.4201215.3172.874.344.6
Research & Development
149.8158.3146.2194--
Other Operating Expenses
-5.2-16.9-5.2-8.9--0.3
Operating Expenses
457342.4356.3357.97746.8
Operating Income
-447.8-330-321.8-311.3-197-105.2
Interest Expense
-11.9-14.4-17.6-4.2-0.1-0.2
Interest & Investment Income
9.85.26.94.90.90.1
Currency Exchange Gain (Loss)
-10.3-10.3-6.3-13.42.40.6
Other Non Operating Income (Expenses)
-9.57.4-4.5-2.8-0.2
Pretax Income
-469.7-342.1-343.3-326.8-193.8-104.5
Income Tax Expense
0.40.40.30.1--
Net Income
-470.1-342.5-343.6-326.9-193.8-104.5
Net Income to Common
-470.1-342.5-343.6-326.9-193.8-104.5
Net Income Growth
------
Shares Outstanding (Basic)
426368307257194180
Shares Outstanding (Diluted)
426373311260194180
Shares Change
19.54%20.10%19.57%33.86%7.97%166.96%
EPS (Basic)
-1.10-0.93-1.12-1.27-1.00-0.58
EPS (Diluted)
-1.11-0.93-1.12-1.30-1.00-0.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-351.1-267-227.9-278.4-173.5-130.3
Free Cash Flow Per Share
-0.82-0.71-0.73-1.07-0.89-0.72
Gross Margin
13.14%19.87%74.84%80.90%--152.88%
Operating Margin
-639.71%-528.85%-698.05%-540.45%-871.68%-275.39%
Profit Margin
-671.57%-548.88%-745.34%-567.53%-857.52%-273.56%
Free Cash Flow Margin
-501.57%-427.89%-494.36%-483.33%-767.70%-341.10%
EBITDA
-439.6-328.6-320.7-310.2-195.8-104
EBITDA Margin
------272.25%
D&A For EBITDA
8.21.41.11.11.21.2
EBIT
-447.8-330-321.8-311.3-197-105.2
EBIT Margin
------275.39%
Revenue as Reported
----22.638.5